



World Health
Organization

CONSOLIDATED HIV STRATEGIC
INFORMATION GUIDELINES

DRIVING IMPACT THROUGH PROGRAMME MONITORING AND MANAGEMENT

WEB ANNEX A
MAPPING OF 2020 INDICATORS TO 2015
GUIDELINE INDICATORS

APRIL 2020

The text of the Consolidated strategic information guidelines, April 2020, is available online at: <https://apps.who.int/iris/bitstream/handle/10665/331697/9789240000735-eng.pdf>

Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management. Web Annex A. Mapping of 2020 indicators to 2015 guideline indicators

ISBN 978-92-4-000436-8 (electronic version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Web Annex A. Mapping of 2020 indicators to 2015 guideline indicators. In: Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management. Geneva: World Health Organization; 2020. Licence: **CC BY-NC-SA 3.0 IGO**.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication forms part of the WHO guideline entitled *Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management*. It is being made publicly available for transparency purposes and information, in accordance with the *WHO handbook for guideline development*, 2nd edition (2014).

WEB ANNEX A MAPPING OF 2020 INDICATORS TO 2015 GUIDELINE INDICATORS

2015 national indicators by reference number & short name	Status	Corresponding 2020 indicator reference number & short name
NEEDS.1 People living with HIV	Retained	BI.1 People living with HIV
NEEDS.2 Key populations (size)		(Included in KP.1 Coverage of HIV prevention (KP))
NEEDS.3 Coinfection	Retired	
NEEDS.4 ART eligibility	Retired	
NEEDS.5 HIV-positive pregnant women		(Included in BI.4 Final MTCT rate)
NEEDS.7 Key population experience with discrimination	Retired	
KPOP.1/HTS.7 HIV testing coverage of key populations	Modified	Additional indicator TL.8 Coverage of HIV testing in prevention services
KPOP.2 Needle–syringe distribution	Retained	KP.2 Needles and syringes distributed
KPOP.3 Key population ART coverage	Modified	AV.1 PLHIV on ART – with KP disaggregation
PREV.1.a Condom use among SW	Modified	Consolidated into one indicator with specific definitions for each group: PR.1 Condom use (KP & Gen pop)
PREV.1.b Condom use among MSM	Modified	
PREV.1.c Condom use among PWID	Modified	
PREV.1.d Condom use in general population	Modified	
PREV.5 Facility-level injection safety	Retained	Dfl.1 Facility-level injection safety
PREV.7 Facility-level blood safety	Modified	DfB.1 Facility-level blood safety
PREV.9 ANC syphilis screening coverage	Retained	ST.1 Syphilis screening coverage (in ANC)
PREV.10 Syphilis treatment	Retained	ST.2 Syphilis treatment coverage (in ANC)
HTS.1 People living with HIV diagnosed	Modified	TL.1 PLHIV who know their HIV status
HTS.2 HTS scale-up	Modified	TL.2 HTS testing volume and positivity
HTS.3 HTS retest	Retained	Additional indicator TL.8 HIV Retesting to verify diagnosis at ART initiation
HTS.4/MTCT.1 PMTCT testing coverage	Retained	Additional indicator MT.8 HIV testing among pregnant women
HTS.5/MTCT.6 Coverage of early infant diagnosis	Retained	VT.2 EID coverage
LINK.1 Linkage to care	Modified	TL.3 Linkage to ART
LINK.2 HIV care coverage	Retired	
LINK.3 Enrolment in care	Retired	
LINK.4/MTCT.10 Unmet need for family planning	Retired	
LINK.5 TB screening coverage in HIV care	Modified	Dft.1 TB screening coverage among new ART patients
LINK.12 TB prevalence in HIV care	Modified	TB.4 PLHIV with active TB disease
LINK.17 IPT/LTBI treatment coverage	Modified	TB.1 TPT initiation
LINK.27 Hepatitis B screening	Retired	
LINK.28 Hepatitis C screening	Retained	DfH1. HCV screening coverage

2015 national indicators by reference number & short name	Status	Corresponding 2020 indicator reference number & short name
ART.1 New ART patients	Retained	AV.4 New ART patients
ART.2 ART coverage 1	Retired	
ART.3 ART coverage 2	Modified	AV.1 PLHIV on ART
ART.4 Late ART initiation	Modified	AV.5 Late ART initiation
ART.5 ART retention	Modified	AV.2 Total attrition from ART
ART.6 Medium-term ART outcomes	Retired	
ART.7 ART adherence proxy	Retained	Additional indicator AV.11 ART adherence proxy (ARV refills)
ART.8/VLS.2 Viral load testing coverage	Modified	AV.6 VL testing coverage
ART.9/ART/15/VLS.1 Viral load suppression at 12 months	Retired	
ART.10 ARV stock-out	Retained	Additional indicator AV.10 ARV medicine stock-out
ART.11 ART survival	Retired	
ART.12 Toxicity prevalence	Retained	AV.9 ARV toxicity prevalence
VLS.3 Viral suppression	Modified	AV.3 PLHIV who have suppressed VL
VLS.4 Viral load monitoring	Retired	
MTCT.2 PMTCT ART coverage	Modified	VT.4 ART coverage in pregnant women
MTCT.3 ART retention	Modified	Additional indicator MT.12 ART retention PMTCT
MTCT.4 Coverage of infant ARV prophylaxis	Retained	VT.3 Infant ARV prophylaxis coverage
MTCT.5 ARV coverage for breastfeeding patients	Modified	VT.5 ART coverage in breastfeeding mothers
MTCT.7 Final MTCT transmission rate	Retained	BI.4 Final MTCT rate
MTCT.8 Final outcome status	Retained	VT.6 Final outcome of PMTCT
MTCT.9 Co-trimoxazole prophylaxis coverage	Retained	Additional indicator MT.13 CTX coverage exposed infants
IMP.1 AIDS-related deaths	Retained	BI.5 AIDS mortality
IMP.2 HIV incidence	Retained	BI.3 New HIV infections (per 1000 population)
IMP.6 Equitable access to ART	Retired	

2015 indicators that were not reviewed or modified


TB-side TB/HIV indicators –

- LINK.13 HIV prevalence among TB patients
- LINK.14 Mortality among HIV-positive TB patients
- LINK.15/HTS.6 HIV testing among TB patients
- LINK.16 ART coverage during TB treatment

HIVDR survey-based indicators –

- ART.14 HIVDR prevalence at ART initiation

Health systems indicators –

- RES.1 Service availability
 - RES.12 Availability
 - RES.13 Quality control of ARV medicines
 - RES.31 Domestic public funding on HIV
 - RES.33 HIV spending on health programmes
 - RES.35 Country progress in domestic funding
 - RES.36 Domestic private expenditure
 - RES.37 Unit cost of HIV interventions
 - NEEDS.6 General stigma
- 

For more information, contact:

World Health Organization
Department of HIV/AIDS
20, avenue Appia
1211 Geneva 27
Switzerland

Email: hiv-aids@who.int

www.who.int/hiv

ISBN 978-92-4-00436-8

